newsfilter
← Latest News
Business Wire·

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

28-day dosing regimen completed by several patients to date Efficacy data from fully funded Phase 2 trial is expected in first half of 2022 MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company